Covalent Small Molecule RVJB59 Stabilizes Two Cancer-Driving p53 Mutants
- p53 is the tumor suppressor most frequently inactivated in cancer, and hotspot mutations such as R280K and R273H destabilize the folded DNA-binding domain, making mutant p53 reactivation a long-standing 'undruggable' target class.
- The study describes RVJB59, a small molecule from a tryptophanol-derived oxazoloisoindolinone series, designed to covalently engage mutant p53 protein rather than bind it only reversibly.
- Biophysical thermal-stability assays reported for this compound series show increased melting stability of mutant p53 DNA-binding domains, consistent with partial restoration of a more folded, wild-type-like conformation.
- Combining covalent engagement with thermostabilization supports a mutant-reactivation strategy aimed at restoring p53 tumor-suppressor function in cancers driven by the R280K and R273H mutations.
Mutant p53 reactivation is the target class every oncology med chemist wants a win on — most p53 lesions are destabilizing loss-of-function, not a clean druggable pocket, so 'fix the fold' beats 'block the site.' RVJB59's angle — covalent engagement plus measurable thermal stabilization of R280K and R273H DBDs — is mechanistically the right read: lock a reactive residue, nudge the folding equilibrium back toward a wild-type-like conformation. My first questions are the covalent-chemist ones: which residue, what warhead, how clean is selectivity across the proteome — thermal-shift data alone won't settle that. Worth benchmarking against PC14586/rezatapopt's reversible pocket-binding approach for R175H; different mutant, different chemotype, same underlying bet. Reads as solid hit-to-lead chemical biology, not anything near clinic-ready.